PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 8, 2026Cancer Letters1 citationsOpen Access

Human neural stem cell-derived extracellular vesicles improve cognitive function following glioma chemoradiation therapy

View Full Paper
CHCasey HudsonRKRobert P. KrattliSESanad M. El-Khatib

Key Points

  • The research aims to explore the effects of human neural stem cell-derived extracellular vesicles (EVs) on cognitive impairment caused by glioma chemoradiation therapy.
  • Evaluated EVs from GMP-grade hNSCs in glioma-bearing and non-tumor adult mice.
  • Mice underwent fractionated cranial radiation therapy and treatment with temozolomide.
  • Assessed cognitive function, synaptic integrity, gliosis, and gene expression after EV administration.
  • EV administration improved memory performance in RT-TMZ exposed mice.
  • Shef6-EVs extended survival in glioma-bearing mice without chemoradiotherapy.
  • Treatment did not interfere with the anti-tumor efficacy of RT-TMZ, maintaining tumor control.

Abstract

ABSTRACT Cranial radiation therapy (RT) with concomitant and adjuvant temozolomide (TMZ; Stupp protocol) prolongs glioma survival but frequently results in persistent cognitive impairment. Human neural stem cell (hNSC)-derived extracellular vesicles (EVs) are a promising acellular therapy whose bioactive cargo can modulate neuroinflammation and synaptic integrity. We evaluated two EVs derived from GMP-grade hNSCs (Shef6 and UCI-191) in syngeneic glioma-bearing and non-tumor adult mice treated with fractionated cranial RT (3 × 8.67 Gy) together with concomitant low-dose (25 mg/kg) and adjuvant high-dose (66.7 mg/kg, intraperitoneal) TMZ. EV administration improved memory performance in RT-TMZ–exposed mice and, notably, Shef6-EVs also extended survival in glioma-bearing mice in the absence of chemoradiotherapy. Immunofluorescence analyses demonstrated attenuated gliosis and preservation of synaptic integrity in EV-treated RT-TMZ-exposed brains, while bulk transcriptomic profiling identified distinct neuroprotective gene expression pathways associated with each EV source. Critically, neither Shef6 nor UCI-191 EVs diminished or interfered with the anti-tumor efficacy of RT-TMZ. These data support hNSC-derived EVs as a translational strategy to mitigate treatment-related neurotoxicity while preserving oncologic benefit in a clinically relevant glioma model. • Systemic administration of GMP-grade hNSC-EVs after RT-TMZ restores cognitive performance in both non-tumor and glioma-bearing mice. • hNSC-EV treatment attenuates astrogliosis and microglial activation and preserves synaptic density in brain regions critical for learning and memory. • hNSC-EVs do not compromise the anti-tumor efficacy of RT-TMZ, as tumor control and survival are maintained in glioma-bearing animals. • Peripheral organ histology shows no gross toxicity following repeated systemic EV administration. • Transcriptomic profiling reveals distinct but convergent neuroimmune and neuroprotective gene-expression programs engaged by each EV line, consistent with the observed rescue of cognition and synaptic integrity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hudson et al. (2026) studied this question.

synapsesocial.com/papers/69fd7fa1bfa21ec5bbf0836bhttps://doi.org/10.1016/j.canlet.2026.218564
Ask AI
Helpful
Bookmark
Share
View Full Paper